Rubicon Organics Q1 2024 Earnings Report
The Dales Report » Cannabis
by Bill McNarland
14h ago
The TDR Three Key Takeaways regarding Rubicon Organics Q1 2024 Earnings Report: Rubicon Organics reports Q1 2024 net revenue of $8.9 million, a 1% increase from Q1 2023. Adjusted EBITDA loss of $0.4 million, compared to a profit of $1.7 million in Q1 2023. WildflowerTM tops Canadian topical market with a 30.6% share. Rubicon Organics Inc. (OTCQX: ROMJF, ROMJ:CA), a producer of organic cannabis, announced its earnings report for the first quarter of 2024. The company reported net revenue of $8.9 million, marking a 1% increase from $8.8 million in Q1 2023. Adjusted EBITDA showed a loss of $0 ..read more
Visit website
Cannabis Legalization and Cannabis Industry: Experts View
The Dales Report » Cannabis
by Bill McNarland
14h ago
The TDR Three Key Takeaways regarding Expert views on Cannabis Legalization and Rescheduling: Dan Ahrens believes cannabis legalization takes a significant leap with Biden’s rescheduling move. Anthony Coniglio thinks new development impacts the SAFE Banking Act. Rescheduling is seen as a milestone, not the end, in cannabis legalization journey, Anthony Coniglio stated.  On May 16, 2024, President Joe Biden’s announcement of the federal rescheduling of cannabis marked a pivotal moment in the cannabis legalization and cannabis industry. The shift from Schedule I to Schedule III signals a ..read more
Visit website
Marijuana Rescheduling Provides Justice and Economic Opportunity
The Dales Report » Cannabis
by Bill McNarland
1d ago
The TDR Three Key Takeaways regarding Marijuana Rescheduling and Economic Opportunity: Biden’s marijuana rescheduling aims to address past policy failures. Rescheduling enables broader medical research on marijuana. Bipartisan support grows for comprehensive marijuana reform. In a significant policy shift, the Justice Department is moving to reschedule marijuana from a Schedule I to a Schedule III drug, recognizing its medical benefits and addressing longstanding inequities in its federal treatment. President Joe Biden announced the move in a video on Thursday, emphasizing his administratio ..read more
Visit website
AYR Wellness Q1 2024 Earnings Report
The Dales Report » Cannabis
by Bill McNarland
2d ago
The TDR Three Key Takeaways regarding AYR Wellness Q1 2024 Earnings Report: AYR Wellness reports Q1 2024 revenue of $118.0 million, a 2.8% increase from Q4 2023. Adjusted EBITDA for Q1 2024 was $29.1 million, up over 10% year-over-year. AYR Wellness achieved positive free cash flow for the quarter. AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF), a vertically integrated U.S. multi-state cannabis operator, announced its earnings report for the first quarter of 2024, highlighting continued progress in key operational metrics and cost controls. For Q1 2024, AYR Wellness reported revenue of $118.0 ..read more
Visit website
TILT Holdings Q1 2024 Earnings Report
The Dales Report » Cannabis
by Bill McNarland
2d ago
The TDR Three Key Takeaways regarding TILT Holdings Q1 2024 Earnings Report: TILT Holdings reports Q1 2024 revenue of $37.5 million, a decrease from $42.3 million in Q1 2023. Adjusted EBITDA improved to $38,000 from $(79,000) in Q1 2023. Net loss increased to $9.7 million compared to $4.9 million in Q1 2023. TILT Holdings Inc. (Cboe: TILT, OTCQB: TLLTF), a global provider of cannabis business solutions, reported its earnings report for the first quarter of 2024, noting ongoing challenges and strategic adjustments. Revenue for Q1 2024 was $37.5 million, down from $42.3 million in the same pe ..read more
Visit website
Cresco Labs’ Earnings report: Interview with CEO Charlie Bachtel
The Dales Report » Cannabis
by Bill McNarland
2d ago
The TDR Three Key Takeaways regarding Cresco Labs’ Q1 earnings  Cresco Labs shows strong Q1 with $184M in revenues and $92M gross profit. Strategic foresight in Cresco Labs leads to canceling M&A for efficiency. Cresco Labs’ strategic market expansions poised to leverage federal changes. Cresco Labs’ (CSE: CL, OTCQX: CRLBF) Q1 earnings report showcased its financial health and strategic changes, making a significant impact through operational efficiency and adept market execution in the cannabis industry.  Cresco Labs announced a strong start to the year with Q1 revenues reach ..read more
Visit website
Revised Projections For The Global Cannabis Market
The Dales Report » Cannabis
by Bill McNarland
3d ago
The TDR Three Key Takeaways regarding cannabis market and its revised projections: U.S. cannabis sales are forecast to hit $33.6 billion by the end of 2023. The global cannabis market is projected to reach $197.74 billion by 2028. North America’s cannabis market sees a promising 26.65% CAGR until 2032 The North American legal cannabis market is experiencing growth, with recent studies projecting significant sales and economic impact increases. According to a report by ResearchAndMarkets.com, the North America’s legal cannabis market is expected to grow at a compound annual growth rate (CAGR ..read more
Visit website
Organigram: Q2 Fiscal Performance and Strategic Plans
The Dales Report » Cannabis
by Bill McNarland
3d ago
The TDR Three Key Takeaways regarding Organigram and Q2 Fiscal Performance: Organigram records net loss despite a strong market position. Jupiter investment substantially increased Organigram’s cash reserves significantly. Organigram plans strategic expansion into new international markets. Organigram Holdings Inc. (NASDAQ: OGI, TSX: OGI) yesterday announced its financial results for the second quarter of Fiscal 2024, reflecting a mixed performance marked by significant achievements. Despite recording a higher net loss, the company remains optimistic about its future, supported by strategic ..read more
Visit website
Glass House Brands Q1 2024 Earnings Release
The Dales Report » Cannabis
by Bill McNarland
3d ago
The TDR Three Key Takeaways regarding Glass House Brands Q1 2024 Earning Release : Glass House reports a 9% annual increase in Q1 2024 revenue, reaching $30.1 million. Biomass production surges 28% YOY without expanding the cultivation area. Glass House projects Q2 revenue to hit a record $52-$54 million. Glass House Brands Inc. (OTCQX: GLASF, GHBWF) reported its financial results for the first quarter of 2024, showing progress and areas for improvement. Despite a net loss, the company displayed significant growth in key operational metrics and remains positive about its future. For Q1 2024 ..read more
Visit website
Medical Cannabis Markets’ Update in Germany and the UK
The Dales Report » Cannabis
by Bill McNarland
4d ago
The TDR Three Key Takeaways regarding Germany and Medical Cannabis: Germany is gearing up to initiate pilot programs for state-controlled cannabis shops, focusing on scientific purposes in the medical cannabis industry. UK’s private medical cannabis market contrasts with Germany’s approach. Pilot cannabis programs in Germany could model future European laws. Germany’s progression in the cannabis sector is marked by innovative approaches to cannabis legalization and medical cannabis. The country is gearing up to initiate pilot programs for state-controlled cannabis shops, focusing on scienti ..read more
Visit website

Follow The Dales Report » Cannabis on FeedSpot

Continue with Google
Continue with Apple
OR